Expert Opinion on Drug Safety

Article	Citations
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis	118
Neurologic complications of immune checkpoint inhibitors	77
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis	62
Tackling antimicrobial resistance across sub-Saharan Africa: current challenges and implications for the future	46
Biologics in the treatment of pustular psoriasis	39
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety	38
An overview of statin-induced myopathy and perspectives for the future	36
Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis	36
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients	35
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib	35
Up-to-date expert opinion on the safety of recently developed antipsychotics	33
Gastrointestinal and cardiovascular adverse events associated with NSAIDs	32
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients	32
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines	31
A safety evaluation of aripiprazole in the treatment of schizophrenia	29
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia	28
Adverse events related to topical drug treatments for acne vulgaris	27
CGRP inhibitors for migraine prophylaxis: a safety review	26
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review	26
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system	26
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database	26
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion	25
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis	24
Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis	24
Long-term safety of ketamine and esketamine in treatment of depression	24

Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases	23
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence	23
Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits	22
Safety of current therapies for onychomycosis	21
Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects	21
Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma	19
Deprescribing in migraine	19
A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis	19
The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses	19
Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease	18
Current and emerging long-acting antipsychotics for the treatment of schizophrenia	18
Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review	18
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data	18
Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery disease patients undergoing percutaneous coronary	17
The safety of baricitinib in patients with rheumatoid arthritis	17
Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge	17
A drug safety evaluation of risankizumab for psoriasis	17
Safety and efficacy of P2Y12inhibitor monotherapy in patients undergoing percutaneous coronary interventions	17
Tafenoquine: a toxicity overview	16
Treatment of dyslipidemia in kidney transplantation	16
Gastroenterological safety of IL-17 inhibitors: a systematic literature review	16
The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability	16
Long-term drug treatment in multiple sclerosis: safety success and concerns	16
Selective serotonin reuptake inhibitors and the risk of congenital anomalies: a systematic review of current meta-analyses	16
Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review	15
Current treatment options and safety considerations when treating adult-onset Still’s disease	15
The risk of cardiovascular complications with current obesity drugs	14
The therapeutic potential of psilocybin: a systematic review	14
Safety and efficacy of pharmacologic agents used for rapid tranquilization of emergency department patients with acute agitation or excited delirium	14
Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions	14
Statin use and safety concerns: an overview of the past, present, and the future	14
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism	14
Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections	14
Risks and benefits of reducing the number of drugs to treat HIV-1 infection	14
Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions	14
Improving the safety of intravenous iron treatments for patients with chronic kidney disease	14
Current strategies for managing intestinal failure-associated liver disease	13
An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles	13
Safety and tolerability of spesolimab in patients with ulcerative colitis	13
Antimicrobial resistance and the post antibiotic era: better late than never effort	13
Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer	13
The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis	12
Safety of dupilumab in patients with atopic dermatitis: expert opinion	12
Safety of antithyroid drugs in pregnancy: update and therapy implications	12
Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review	12
Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation	12
A systematic review on pediatric medication errors by parents or caregivers at home	12
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges	12
Safety update of etanercept treatment for moderate to severe plaque psoriasis	12
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation	11

Safety of current recombinant human growth hormone treatments for adults with growth hormone deficiency and unmet needs	11
Oral isotretinoin for acne: a complete overview	11
Safety of the current drug treatments for vitiligo	11
Online information discrepancies regarding safety of medicine use during pregnancy and lactation: an IMI ConcePTION study	11
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids	11
A long-term open-label safety study of galcanezumab in Japanese patients with migraine	11
Cilastatin as a protective agent against drug-induced nephrotoxicity: a literature review	11
The safety of current pharmacotherapeutic strategies for osteosarcoma	11
Thalidomide: history, withdrawal, renaissance, and safety concerns	10
Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study	10
Safety evaluations of adalimumab for childhood chronic rheumatic diseases	10
Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?	10
Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-a	10
The effect of patient sex on the efficacy and safety of anticancer immunotherapy	10
Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review	10
Safety and tolerability of preventive treatment options for chronic migraine	10
The safety of JAK kinase inhibitors for the treatment of myelofibrosis	10
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy	10
OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation	10
The relationship between atypical antipsychotics drugs, QT interval prolongation, and torsades de pointes: implications for clinical use	10
Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness	10
Long-term safety of approved biologics for ulcerative colitis	10
Expert opinion on sonidegib efficacy, safety and tolerability	10
Can ketamine be a safe option for treatment-resistant bipolar depression?	9
Concerns about the safety of anti-TNF agents when treating rheumatic diseases	9
Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients	9
Systematic review and meta-analysis on the safety of dalbavancin	9
Safety of topical interventions for the treatment of actinic keratosis	9
The safety of medications used to treat peripheral neuropathic pain, part 1 (antidepressants and antiepileptics): review of double-blind, placebo-controlled, randomized clinical trials	9
Toward digital-based interventions for medication adherence and safety	9
Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis	9
Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products	9
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis	9
Anticholinergic medications and risk of dementia in older adults: Where are we now?	9
Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor	9
Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system	9
Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry	9
Persistent sexual dysfunction after SSRI withdrawal: a scoping review and presentation of 86 cases from the Netherlands	9
Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization	9
Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection	9
Evaluating safety in hyaluronic acid lip injections	9
Safety and tolerability evaluation of erenumab for the preventive treatment of migraine	8
Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?	8
Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system	8
Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which?	8
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review	8
Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors	8
Nothing is perfect: the safety issues of integrase inhibitor regimens	8
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials	8
Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management	8
Adverse drug reactions in elderly: a five-year review of spontaneous reports to the Portuguese pharmacovigilance system	8
Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment	8
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal	8
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia	8
Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan	8
How can we manage the cardiac toxicity of immune checkpoint inhibitors?	8
Safety of injectable semaglutide for type 2 diabetes	8
Is the lack of evidence in older adults with cancer compromising safety?	8
Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs	8
An umbrella review of systematic reviews on contributory factors to medication errors in health-care settings	8
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability	8
Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness	8
Safety considerations when managing gastro-esophageal reflux disease in infants	8
Safety of repository corticotropin injection as an adjunctive therapy for the treatment of rheumatoid arthritis	8
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment	7
The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects	7
A new paradigm in adverse drug reaction reporting: consolidating the evidence for an intervention to improve reporting	7
A safety review of drugs used for the treatment of retinopathy of prematurity	7
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine	7
Intravenous vs intravenous plus aerosolized colistin for treatment of ventilator-associated pneumonia – a matched case–control study in neonates	7
Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system	7
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides	7
Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients	7
A reappraisal of the role of fever in the occurrence of neurological sequelae following lithium intoxication: a systematic review	7
The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer	7
Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice	7
Pharmacovigilance of anti-cancer medicines: opportunities and challenges	7
A review of hydroxyurea-related cutaneous adverse events	7
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study	7
Safety of treatment options available for postoperative pain	7

Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer	7
Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions	7
Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom	7
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension	7
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	7
Safety of intranasal corticosteroids for allergic rhinitis in children	7
The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies	6
Safety of treating acute liver injury and failure	6
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial	6
Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials	6
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma	6
Safety of current treatments for paroxysmal nocturnal hemoglobinuria	6
Introducing sexual dysfunction in mental care	6
The safety of current and emerging therapies for multiple myeloma	6
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer	6
Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections	6
Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics	6
A safety review of approved intrathecal analgesics for chronic pain management	6
Safety considerations of current drug treatment strategies for nosocomial pneumonia	6
Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis	6
SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties	6
Drug-induced retroperitoneal fibrosis: a case/non-case study in the French PharmacoVigilance Database	6
Hepatotoxicity of FDA-approved small molecule kinase inhibitors	6
Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)	6
Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy	6
Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data	6
Post-marketing safety surveillance of erenumab: new insight from Eudravigilance	5
Resident and family engagement in medication management in aged care facilities: a systematic review	5
New and emerging cardiovascular and antihypertensive drugs	5
Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance	5
Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data	5
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance	5
Reporting, handling, and subjective importance of adverse drug reactions among general practitioners: an exploratory cross-sectional survey	5
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents	5
Effectiveness and sustainability of deprescribing for hospitalized older patients near end of life: a systematic review	5
Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study	5
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU	5
Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome	5
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis	5
Impact of the COVID-19 pandemic on clinical trials with drugs	5
Immune-mediated inflammatory disease patients’ preferences in adverse drug reaction information regarding biologics	5
Measuring drug burden in older adults with intellectual disabilities: Critical issues for consideration in finding the optimal measure to improve safety of medicines use	5
Cardiovascular risks associated with protease inhibitors for the treatment of HIV	5
FDA Biosimilar Action Plan: could improving pharmacovigilance of biologics improve patient and physician confidence in biosimilars?	5
Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review	5
Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis	5
Combining two CGRP inhibitors to treat migraine	5
A systematic review of digital technology and innovation and its potential to address anti-corruption, transparency, and accountability in the pharmaceutical supply chain	5
Safety of secukinumab for the treatment of active ankylosing spondylitis	5
How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting	5
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice	5
Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review	5
Safety of systemic treatments for Behçet’s syndrome	5
Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis	5
A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs	5
Drug induced stuttering: pharmacovigilance data	5
Cardiac adverse effects of antiseizure medications	5
Comment about the safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin	4
Anti-inflammatory strategies for atherosclerotic artery disease	4
Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review	4
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals	4
An update on the safety of apremilast for the treatment of plaque psoriasis	4
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus	4
Safety evaluation of secukinumab in pediatric patients with plaque psoriasis	4
A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug	4
Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson’s disease	4
Phenytoin and damage to the cerebellum – a systematic review of published cases	4
Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors	4
Safety evaluation of perampanel as monotherapy or first adjunctive therapy in patients with epilepsy	4
Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis	4
Underreporting of Adverse Drug Events: a Look into the Extent, Causes, and Potential Solutions	4
Comparative safety review of current pharmacological treatments for interstitial cystitis/ bladder pain syndrome	4
The Safety of Medications used to Treat Peripheral Neuropathic Pain, Part 2 (Opioids, Cannabinoids and Other Drugs): review of Double-Blind, Placebo-Controlled, Randomized Clinical Trials	4
Ibrutinib plus rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia: a safety evaluation	4
Safety of non-hormonal medications for managing hot flashes	4
Risks and benefits of current and novel drugs to treat agitation in Alzheimer’s disease	4
Effect of drug interactions between carbapenems and valproate on serum valproate concentration: a systematic review and meta-analysis	4
Improving the data quality of spontaneous ADR reports: a practical example from Malta	4
A comparative review of current topical antibiotics for impetigo	4
Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system	4
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma	4
Safety considerations when using non-ergot dopamine agonists to treat Parkinson’s disease	4
Trends and concerns of potentially inappropriate medication use in patients with cardiovascular diseases	4
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma	4
Malignant syndromes: current advances	4
Pharmacovigilance approaches to study rare and very rare side-effects: the example of clozapine-related DiHS/DRESS syndrome	4
Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review	4
Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis	4
A review of potential neuropathological changes associated with ketamine	4
A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy	4
Safety evaluation of oliceridine for the management of postoperative moderate-to-severe acute pain	4
Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy	4
Novel uses of ketamine in the emergency department	4
Assessment of suspected adverse drug reactions in elderly patients with diabetes mellitus based on a Portuguese spontaneous reporting database: analysis of reporting from 2008 to 2018	4
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV	4